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Background: Penile cancer is an uncommon malignancy in developed countries, but the incidence is as high as
10% to 20% of all male cancers in some developing countries. There is a paucity of published data on this subject
in our setting. This study describes the clinicopathological presentation and treatment outcome of this condition in
our environment, and highlights challenges associated with the care of these patients and proffers solutions for
improved outcome.
Methods: This was a retrospective study of histologically confirmed cases of penile cancer seen at Bugando Medical
Centre between January 2004 and December 2013.
Results: There were 236 penile cancer patients representing 2.2% of all male malignancies during the study period. The
median age was 47 years with a modal age group of 41 to 50 years. Of the 236 patients, 147 (62.3%) had severe
phimosis. The majority of patients (89.8%) were uncircumcised. A history of human papilloma virus (HPV) was
reported in 12 (5.1%) cases. One hundred eighty-two (77.1%) patients reported history of cigarette smoking. Seven
(6.7%) patients were human immunodeficiency virus (HIV) positive. The majority of the patients (68.6%) presented
with Jackson’s stages III and IV. Squamous cell carcinoma was the most common histopathological type (99.2%).
Lymph node metastasis was recorded in 65.3% of cases, and it was significantly associated with the tumor size,
histopathological subtype, histopathological grade, lympho-vascular invasion, positive resection margins, and
urethral involvement (P < 0.001). Distant metastasis accounted for 4.2% of cases. The majority of patients (63.1%)
underwent partial penectomy. Chemotherapy and radiotherapy were given in 14 (5.9%) and 12 (5.1%) patients,
respectively. Complication and mortality rates were 22.0% and 4.2%, respectively. HIV positivity, histopathological
stage and grade of the tumor, and presence of metastases at the time of diagnosis were the main predictors of
death (P < 0.001). The median length of hospitalization was 14 days. Local recurrence was reported in 12 (5.3%)
patients. Data on long-term survivals were not available as the majority of patients were lost to follow-up.
Conclusions: Penile cancer is not rare in our environment. The majority of patients present late with advanced
stage of the disease. Early detection of primary cancer at an early stage may improve the prognosis.
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Penile cancer is reported to be a rare malignancy in the
Western world accounting for less than 1% of adult male
cancers [1]. The incidence in Europe and the United States
is 0.1 to 0.9 per 100,000 and 0.7 to 0.9 per 100,000 men,
respectively [1,2]. However, in some developing countries,
the incidence rate of penile cancer is much higher, ac-
counting for up to 10% to 20% of malignant disease in
men [2-4]. Incidence also varies according to racial group,
ethnicity, and geographical location. Social and cultural
habits, hygienic and religious practices interfere signifi-
cantly with risk factors [5].
The most important etiologic factor of penile cancer is
the presence of an intact foreskin. Penile cancer is rarely
seen in Jewish individuals, who are circumcised at birth
[6]. The risk of this disease in uncircumcised men is ap-
proximately threefold higher than that of circumcised men
[7]. Other factors associated with increased risk of penile
cancer include low socio-economic status, cigarette smok-
ing, human papilloma virus (HPV) infection, lack of penile
hygiene, phimosis, and penile inflammation [8].
Although penile cancer may occur at any age, including
childhood, it mostly affects the elderly, with a peak inci-
dence around the sixth and seventh decades [9]. While in
the Western world penile cancer is a disease of older pa-
tients, with most being diagnosed after the age of 50 years
[2,9], penile cancer in African population tends to present
at a young age with advanced disease and associated poor
prognosis [4,10-15].
Patients with cancer of the penis tend to delay seeking
medical attention, with 15% to 50% delaying medical at-
tention for more than 1 year from onset [16]. This delay is
attributed to embarrassment, guilt, fear, ignorance, and
personal neglect. Patients often try to treat themselves
with various skin creams and lotions. These may appear to
be effective for a time, which further delays the diagnosis
and worsens the prognosis. Delays may also attributable to
the physician. Some patients with penile cancer report that
they receive various salves and antibiotics from their
primary care physicians before they see a urologist. A
delay in diagnosis and therapy not only affects the like-
lihood of survival but also limits the ability to retain a
functioning and cosmetically satisfactory result [16-18].
The management of penile cancer in resource-limited
countries like Tanzania poses major diagnostic and thera-
peutic challenges which need to be addressed. Late presen-
tation with advanced lesion coupled with lack of diagnostic
(such as computed tomography (CT) scan and magnetic
resonance imaging (MRI)) and therapeutic facilities such as
radiotherapy services are among the hallmarks of the
disease in developing countries including Tanzania. The
outcome of treatment of penile cancer in most develop-
ing countries has been poor because the majority of these
patients present late to the hospital with advanced stage.This is partly due to paucity of local data regarding this
condition and lack of community awareness on the im-
portance of early reporting to hospital for early diagnosis
and treatment. This study was conducted to describe the
pattern and treatment outcome of penile cancer patients
treated at our center and to highlight challenges associated
with the care of these patients and proffer solutions for
improved outcome.
Methods
Study design and setting
This was a retrospective study of histologically confirmed
cases of penile cancer seen at Bugando Medical Centre
between January 2004 and December 2013. Bugando
Medical Center is a tertiary care and teaching hospital
for the Catholic University of Health and Allied Sciences-
Bugando (CUHAS-Bugando) in northwestern Tanzania.
It has 1,000 beds and serves as a referral center for ter-
tiary specialist care for a catchment population of ap-
proximately 13 million people. The hospital has a newly
established oncology department which provides care
for all patients with histopathologically proven cancers,
including penile cancer.
Study population
The study population included all patients who presented
to Bugando Medical Center with histologically confirmed
penile cancer during the study period. Patients with in-
complete data were excluded from the study. The details
of patients were obtained from patients’ files kept in the
medical record department, the surgical wards, operating
theater, and histopathology laboratory. Information was
collected using a preformed questionnaire. Data included
in the questionnaire were age of the patient, risk factors
for penile cancer, clinical presentation, anatomical site,
tumor stage, histopathological type and grade, presence
of lymph node or distant metastases, treatment modalities,
treatment outcome (that is, postoperative complications,
length of hospital stay, and mortality), and follow-up. The
clinical stage of the disease was assigned to each patient
using the Jackson Classification for Cancer of the Penis
[19] as follows: stage I (confined to glans or prepuce),
stage II (invasion into shaft or corpora), stage III (operable
inguinal lymph node metastasis), and stage IV (tumor in-
vades adjacent structures, inoperable inguinal lymph node
metastasis).
Statistical data analysis
The statistical analysis was performed using the Statis-
tical Package for Social Sciences (SPSS) version 17.0 for
Windows (SPSS, Chicago, IL, USA). The median (and IQR)
and ranges were calculated for continuous variables,
whereas proportions and frequency tables were used
to summarize categorical variables. The chi-square (χ2)
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between the independent (predictor) and dependent
(outcome) variables in the categorical variables. The
level of significance was considered as P < 0.05. Multi-
variate logistic regression analysis was used to determine
predictor variables that predicted the outcome.
Ethical consideration
Ethical approval to conduct the study was obtained from
the CUHAS-Bugando/BMC joint institutional ethic review
committee before the commencement of the study.
Results
Socio-demographic profile
During the study period, a total of 11,345 male malig-
nancies were registered at Bugando Medical Centre. Of
these, 248 (2.2%) were histopathologically confirmed penile
cancer (Table 1). Out of these, 12 patients were excluded
from the study due to missing data. Thus, 236 patients
were enrolled into the study. The age of patients at diagno-
sis ranged from 21 to 78 years with the median age of 47
years (IQR = 45 to 49 years). The peak age incidence was
in the 41- to 50-year age group accounting for 43.6% of
cases. One hundred thirty-three (56.4%) patients were
younger than 50 years of age. All of our patients were
blacks of African descent. The majority of them (204
(86.4%)) came from the rural areas located a considerable
distance from Mwanza City, and most of them (212
(89.8%)) had either primary or no formal education.
More than 80% of patients were unemployed, and the
vast majority of these patients (220 (93.2%)) had no identi-
fied health insurance.
Etiological risk factors
Of the 236 patients with penile cancer, 147 (62.3%) had
severe phimosis not allowing the possibility of exposing
the glans. The majority of patients (212 (89.8%)) were un-
circumcised and only 24 (10.2%) patients had circumci-
sion. Of these 24 patients who had circumcision, only 2Table 1 Annual distribution of patients (N = 248)










2004 19 7.7(8.3%) underwent the procedure during the neonatal
period, and in the remaining 22 (91.7%) patients, the pro-
cedure was performed during adolescence and in adult-
hood. HPV infection was reported in 12 (5.1%) cases. One
hundred and eighty-two (77.1%) patients reported history
of cigarette smoking. The number of cigarettes per day
that the patients consumed tobacco was not reported, nor
was the length of time those patients had been tobacco
smokers preventing further statistical analysis to be con-
ducted. One (0.4%) patient developed penile cancer from
a penile human bite scar (Marjolin’s ulcer). This patient
sustained penile human bite injury during oral sexual
intercourse. He was treated successfully and got cured.
Seven months later, a malignant ulcer on the healed
penile scar developed, which was confirmed histopatho-
logically as squamous cell carcinoma. Fifty-four (22.9%)
patients reported history of multiple sexual partners,
and most of them had suffered sexually transmitted dis-
eases once or several times in their adulthood. Human
immunodeficiency virus (HIV) status was known in 104
patients. Out of the 104 patients with known serostatus, 7
(6.7%) were reported to be HIV positive.
Clinicopathological characteristics among patients with
penile cancer at Bugando Medical Centre
The duration of symptoms at presentation ranged from
2 months to 7 years with a median duration of 22 months,
and the majority of patients (164 (69.5%)) presented be-
tween 1 and 5 years of onset of illness. Fifty-two (22.0%)
and 20 (8.5%) patients presented within 1 year and after 5
years of onset of illness, respectively. Two hundred eleven
(89.4%) patients had undergone some form of intervention
in peripheral dispensaries and hospitals before being re-
ferred, with dressing, antibiotics, and inadequate surgical
resection being the most common intervention and some
of them were treated as cases of syphilis. Anatomical site,
Jackson’s stage, tumor size, histopathological type/grade,
and metastases at the time of diagnosis are shown in
Table 2. Regarding the histopathological type, the clas-
sic squamous cell carcinoma (SCC) was the predominant
subtype seen in 199 (85.0%) patients. This was followed by
basaloid subtype in 12 (5.1%), verrucous subtypes in 5
(2.1%), and sarcomatoid in 2 (0.9%) patients. SCC subtype
was not documented in 18 (7.6%) patients. Lymph node
metastasis at the time of diagnosis was significantly associ-
ated with anatomical site (OR = 3.4, 95% CI (2.1 to 9.8),
P = 0.002), tumor size (OR = 2.9, 95% CI (1.1 to 6.4), P =
0.011), histopathological subtype (OR = 6.2, 95% CI (3.1 to
8.6), P = 0.001), histopathological grade (OR = 4.0, 95% CI
(2.2 to 5.6), P = 0.003), lympho-vascular invasion (OR =
2.7, 95% CI (1.8 to 5.4), P = 0.032), positive resection mar-
gins (OR = 3.8, 95% CI (2.6 to 7.1), P = 0.012), and urethral
involvement (OR = 4.3, 95% CI (2.1 to 6.0), P = 0.000) in
multivariate logistic regression analysis. Distant metastasis
Table 2 Anatomical site, Jackson’s stage, tumor size,
histopathological type/grade, and metastasis
Variable Response Frequency Percentages
Anatomical site Glans penis 142 60.1
Glans + shaft 32 13.6
Prepuce only 18 7.6
Glans + prepuce 18 7.6
Shaft + prepuce 14 5.9




Histopathological type Squamous cell
carcinoma
234 99.2
Soft tissue sarcoma 1 0.4
Small-cell carcinoma 1 0.4
Tumor size Less than 2 cm 56 23.7
2 cm or more 180 76.3
Histopathological
grade
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(50.0%), 3 (30.0%), and 1 (10.0%) each, respectively.
Radiological and laboratory investigations
Chest X-rays performed in all (100%) patients confirmed
lung metastasis in three (1.3%) patients. Skeletal survey
revealed bony metastasis in one patient. Abdomino-
pelvic ultrasound performed in 162 (68.6%) patients de-
tected pelvic (iliac) lymph nodes and liver metastases in
84 (51.9%) and 5 (3.1%) patients, respectively. No patient
had a CT scan or MRI examination due to the lack of
these imaging facilities at our center. Liver function tests
were performed in all patients and revealed abnormal
results in ten (4.2%) patients. HIV status was known in
104 patients and revealed positive results in 7 (6.7%)
patients. The CD4+ count among HIV-positive patients
was available in only four patients and ranged from 126to 712 cells/μl with a median of 234 cells/μl (IQR = 230
to 238 cells/μl). VDRL test performed in 98 (41.5%) pa-
tients revealed negative results in all patients.
Treatment modalities
Out of 236 patients, 234 (99.2%) underwent 268 surgical
procedures for penile cancer, and the remaining 2 (0.8%)
patients were unfit for surgery. Of the type of surgical
procedures performed, partial penectomy was the most
frequently performed surgical procedure, accounting for
63.1% of cases (Figure 1). Inguinal lymphadenectomy was
performed in only 16.8% of cases. No patient had pelvic
lymphadenectomy. The use of chemotherapy was docu-
mented in 14 (5.9%) patients. Of these, 1 (7.1%) was given
chemotherapy as a neo-adjuvant therapy, whereas in the
remaining 13 (92.9%) patients, chemotherapy was used as
adjuvant therapy. Cisplatin in combination with other
cytotoxic agents such as bleomycin and methotrexate was
the most commonly used drug. Radiotherapy was used as
adjuvant therapy in only 12 (5.1%) patients.
Clinical outcome and follow-up of patients
A total of 58 postoperative complications were recorded
in 52 patients giving a complication rate of 22.0%. Of
these, surgical site infection (SSI) was the most common
postoperative complication accounting for 44.8% of cases
(Table 2). On multivariate logistic regression analysis, the
rate of SSI was significantly high in HIV-positive patients
as compared with HIV-negative patients (P = 0.003). The
overall length of hospital stay (LOS) ranged from 5 to 34
days with a median of 14 days (IQR = 12 to 16 days. Pa-
tients who developed postoperative complications stayed
longer in the hospital, and this was statistically signifi-
cant (P = 0.012). Out of 236 patients, 226 (95.8%) were
discharged alive. Ten patients died in the hospital giv-
ing a mortality rate of 4.2%. According to multivariate
logistic regression analysis, HIV positivity (OR = 4.4, 95%
CI (2.3 to 8.7), P = 0.011), histopathological stage (OR =
5.2, 95% CI (2.7 to 8.8), P = 0.004) and grade of the tumor
(OR = 3.3, 95% CI (1.3 to 5.1), P = 0.03), and presence of
metastases at the time of diagnosis (OR = 5.6, 95% CI (3.4
to 8.9), P = 0.001) were the main predictors of death.
Follow-up of patients among survivors ranged from 3
to 61 months with a median of 22 months (IQR = 20 to
24 months). At the end of 5 years, only 54 (23.9%) pa-
tients (survivors) were available for follow-up. Cancer re-
currence was reported in 12 (5.3%) patients who had
surgical treatment. All cases of cancer recurrence occurred
from 6 months to 1 year (median = 8 months) after defini-
tive treatment. Tumor size (OR = 1.6, 95% CI (1.1 to 5.0),
P = 0.014), histological grade of the tumor (OR = 2.3, 95%
CI (1.2 to 3.9), P = 0.001), stage of the tumor (OR = 4.2,
95% CI (1.3 to 6.8), P = 0.023), and presence of metastasis
at the time of diagnosis (OR = 2.7, 95% CI (1.8 to 6.8),
Figure 1 Distribution of patients according to the type of surgical procedures performed.
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rence in multivariate logistic regression analysis. Data
on long-term survivals were not available as the major-
ity of patients were lost to follow-up.
Discussion
Cancer of the penis, though rare in developed countries,
constitutes a continuing challenge to urologist and oncol-
ogists practicing in developing countries where the fre-
quency of this disease is as high as 10% to 20% of all male
cancers [2-4]. In this review, penile cancer accounted for
2.2% of all diagnosed male malignancies seen during the
study period in our setting. This figure is higher than
0.1% that was reported by Magoha and Ngumi [15] in
Kenya. Favorito et al. [9] reported a high figure of 5.7%
in northeastern Brazil. There is a marked variation in
the incidence of penile cancer worldwide, with western
countries having a low rate of less than 1% compared
to higher rates reported in many countries in Africa,
Asia, and North America [2-4]. These differences in in-
cidence rates reflect differences in risk factors for penile
cancer between the study settings.
Penile cancer is typically a disease of older men and
rates increase steadily with age [9]. Many studies in devel-
oped countries indicate a higher incidence of the disease
between the sixth and seventh decades of life [9,14,15]. As
reported in other African studies [16,17], the median age
of 47 years in this study was younger than the age de-
scribed in most developed countries; about 10 years differ-
ence has been reported in these studies [17]. In this study,
56.4% of patients were found to be younger than 50 yearsof age in their fourth and fifth decades of life. We could
not found in the literature the reasons for this age differ-
ences, and this needs to be investigated further.
In keeping with other studies performed in developing
countries [14,15], the majority of patients in this series
came from the rural areas located a considerable distance
from the study area, and more than 85% had either primary
or no formal education. This observation has an implica-
tion on accessibility to healthcare facilities and awareness of
the disease.
Phimosis is considered an important risk factor for the
development of penile cancer and is found in approximately
25% to 75% of patients with this cancer in the largest series
[8]. It has been proposed that inadequate hygiene of the pre-
putial sac with consequent accumulation of smegma leads
to a chronic local inflammatory process, contributing to the
genesis of penile cancer [20]. In our study, more than 60%
of patients presented with severe phimosis not allowing the
possibility of exposing the glans. The majority of patients
(89.2%) in this study were uncircumcised. This is in con-
formity with numerous previous reports that indicate penile
cancer to be common among the uncircumcised males
[6,8,10-13,15]. Neonatal circumcision as practised by the
Jews is known to prevent the development of cancer of the
penis, and this is largely mediated by prevention of phimosis
[6,15,20]. However, circumcision in adolescence and in
adults does not prevent the development of penile can-
cer [20]. In our study, only 2 (8.3%) patients underwent
the procedure during the neonatal period, and in 22
(91.7%) patients, the procedure was performed during
adolescence and in adulthood. Uncircumcised men are
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than men who are circumcised [6,20]. In addition, men
who have an unretractable foreskin are ten times more
likely than other men to develop penile cancer [20].
HPV has been reported to be a risk factor in the devel-
opment of penile cancer [21]. Many studies have shown
the presence of HPV types 16 and 18 in penile cancer
[21-23]. The mechanism by which HPV leads to malignant
transformation is likely mediated through two viral genes,
E6 and E7, which are actively transcribed in HPV-infected
cells. The E6 and E7 proteins bind to and inactivate the
host cell’s tumor suppressor gene products p53 and pRb
(retinoblastoma gene), both of which are known negative
regulators of cellular proliferation, leading to uncontrolled
growth [22]. The prevalence of HPV infection in penile
carcinoma ranges widely, from 15% to 71% in different
studies [23]. In the current study, HPV infection was re-
ported in only 5.1% of cases, a figure which is significantly
lower than that reported in the literature [23]. The reason
for the low rate of HPV in our study may be explained by
the fact that patients with penile cancer in our setting are
not routinely screened for HPV infection.
Several studies have shown an association between
penile cancer and smoking. Hellberg et al. [24] found a re-
lationship between penile cancer and smoking that was
direct, dose-related, and independent of other known risk
factors. Harish and Ravi [25] extended these observations
by demonstrating that the consumption of products made
from tobacco is also related to the incidence of penile can-
cer independent of other factors. In our series, we ob-
served a predominance of smokers, representing 77.1% of
cases. This study, despite not having used a control group,
showed that more than three quarter of the patients
with cancer of the penis were smokers, suggesting that
smoking may represent a risk factor for the develop-
ment of penile cancer. The association between smok-
ing and penile cancer can be explained by the fact that
tobacco products (nicotine) usually become concentrated
in smegma, making it carcinogenic, especially in men with
phimosis.
Injury to the penis had been reported to increase the
risk of penile cancer [8]. In the present study, we had
one patient who presented with an early appearance of
penile cancer (Marjolin’s ulcer) developing in a penile
human bite scar. Marjolin's ulcer is a rare and often ag-
gressive cutaneous malignancy that arises in previously
traumatized, degenerated, and chronically inflamed skin
or scar tissue [26]. Marjolin’s ulcers are commonly mis-
taken for an infected ulceration occurring at the scar
tissue sites and may often be overlooked. In our study,
the majority of penile cancers were mistaken for syph-
ilis and were treated with dressing and antibiotics with
no improvement. A high index of suspicion is therefore
required in the management of chronic non-healing penileulcers that are recalcitrant to therapy, and all suspected
lesions should be biopsied.
Multiple sexual partners and sexually transmitted dis-
eases especially genital warts have been reported to in-
creased the risk of developing penile cancer [8]. In the
current study, more than 20% of patients reported history
of multiple sexual partners, and most of them had suffered
sexually transmitted diseases once or several times in their
adulthood. Many studies have shown an association be-
tween penile cancer and a history of multiple sexual part-
ners and early age of first intercourse [6].
Infection with HIV, the virus that causes acquired im-
mune deficiency syndrome (AIDS), is a risk factor for penile
cancer. When a person is HIV positive, their immune
system is less able to fight off early-stage cancer [6,27].
Penile cancer has been observed in HIV-positive men
and in transplant recipients, who carry a 36-fold increase
of the risk of cancer development at any site [27,28]. Al-
though the AIDS epidemic has not led to an increased
incidence of penile cancer in areas such as Uganda, where
HIV infection is widespread, however, there has been a
significantly increased incidence of penile among HIV
patients, and immune suppression is considered a rele-
vant predisposing factor to penile cancer [28,29]. In our
study, HIV status was known in 104 patients, out of
whom 7 (6.7%) were reported to be HIV positive. Men
with AIDS have a higher risk of developing penile cancer.
This higher risk seems to be related to their lowered im-
mune response, but lifestyle factors may also play a role.
In some studies, men with penile cancer who were HIV
positive were more likely to smoke and to be infected with
HPV than HIV-negative men with penile cancer [6,27].
The majority of patients in this study presented late
with an advanced stage of the disease (Jackson’s stages III
and IV) with operable or inoperable inguinal metastases
and tumors involving adjacent structures or distant metas-
tases which is in keeping with other studies performed in
developing countries [9,15]. This finding is of concern
because it is well established that the advanced stage is
strongly correlated with the degree of invasion and prob-
ability of regional and systemic metastases suggesting a
worse prognosis for these patients [30]. The reason for this
late presentation of penile cancer in this locality is due to
the delay in seeking appropriate medical advice as a result
of socio-cultural taboos and ignorance. The late presenta-
tion of cases is an area of cancer care in our center that re-
quires urgent attention. Detecting primary cancer at an
early stage contributes to improved chances for successful
treatment and thus for survival.
Cancer of the penis is usually an epidermoid tumor
arising from the glans penis or the mucosal lining of
the prepuce [15]. In this study, the glans penis was the
most frequent anatomical site involved in 60.1% of cases.
This observation concurs with other studies [9,15] which
Table 3 Distribution of patients according to
postoperative complication
Postoperative complication Frequency Percentages
Surgical site infections 26 44.8
Deep venous thrombosis (DVT) 9 15.5
Chronic pain 8 13.8
Scrotal edema 6 10.3
Wound dehiscence 4 6.9
Fournier’s gangrene 3 5.2
Urethral stricture 2 3.4
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site involved in penile cancer.
The presence of metastases in the regional lymph nodes
is the main factor predicting an unfavorable prognosis
for patients with penile cancer [18,30]. In the present
study, lymph node metastasis at the time of diagnosis
was recorded in 65.3% of cases, and it was significantly
associated with anatomical site, tumor size, histopatho-
logical subtype, histopathological grade, lympho-vascular
invasion, positive resection margins, and urethral in-
volvement. A similar observation was reported by others
[15,18,28]. High lymph node metastasis in our study is
due to the fact that most patients in the present study
present late when the disease is already in advanced stages.
In developing countries like ours, especially in rural areas
with poor living conditions most patients are already in
advanced stages of disease at the time of diagnosis of
penile cancer which has been proven both in the present
study and in the literature [9,15].
Metastatic spread to distant sites (lungs, liver, bone,
and brain) is uncommon and is reported to occur in 1%
to 10% of cases in most large series. Such metastases usu-
ally occur late in the course of the disease after the local
lesion has been treated [28]. Distant metastases in the ab-
sence of regional node metastases are unusual [18,28]. In
our series, distant metastasis was reported in 4.2% of cases
and occurred mainly to the liver, lung, bone, and brain.
Low rate of distant metastasis in this study may be attrib-
uted to by the lack of advanced staging diagnostic facilities
(such as CT scan, MRI, and positron emission tomog-
raphy) in our setting.
The commonest histopathological type in penile cancer
is squamous cell carcinoma occurring in more than 95%
of cases [10,11,13,15]. This finding is in agreement with
the present study in which more than 99% of penile
cancers were squamous cell carcinoma. Other histological
types about 5 in 100 penile cancers (5%) are adenocarcin-
omas, melanoma, soft tissue sarcomas, urethral tumors,
lymphomas, basal cell carcinomas, and metastases; these
types are extremely rare [31].
The treatment modalities of penile cancer include sur-
gery, chemotherapy, and radiotherapy [13,15,32]. Surgery
is considered to be the mainstay of treatment of penile
cancer, with many early-stage patients being cured with
surgery alone [32]. The goals of surgical treatment of penile
cancer include the complete resection of the primary
tumor, with negative margins to reduce the risk of local
recurrences, and pathologic staging of the tumor and in-
guinal lymph nodes to provide necessary prognostic infor-
mation [30]. In keeping with other studies [13,15], surgery
was the most common modality of penile cancer treat-
ment in this study. Of the type of surgical procedures
performed, partial penectomy was the most frequently
performed surgical procedure, accounting for 63.1% ofcases. This observation concurs with what was reported
by Magoha and Ngumi [15] in Kenya. In this study, in-
guinal lympadenectomy was performed in 16.8% of cases
after penectomy, a figure which is higher than that re-
ported in Kenya by Magoha and Ngumi [15]. The overall
prognosis in all stages of penile cancer is known to depend
largely upon the presence or absence of inguinal lymph
node metastases [30].
Recent advances in surgical therapy of penile cancer
including Mohs micrographic surgery, laser therapy, and
reconstructive surgery can provide satisfactory surgical
treatment while minimizing functional loss of the penis
and avoiding the considerable complications associated
with radiotherapy [33,34]. However, none of our patients
had this form of treatment due to lack of facilities for
these treatment modalities at our center.
Chemotherapy has been utilized in the treatment of
advanced penile cancer either alone or in combination with
surgery or radiotherapy. Bleomycin, cisplastin, and metho-
trexate are the most effective, but complete responses
are rare [35]. In the present study, only 5.9% of patients
received chemotherapy and more than two thirds among
those offered chemotherapy defaulted and did not complete
the course. We could not establish the reasons for
non-adherence to chemotherapy in our study due to the
retrospective nature of the study.
Radiotherapy treatment either alone or in combination
with surgery or chemotherapy has been shown to improve
local control rates. However, in our study, only 5.1% of pa-
tients who required radiotherapy had access to this form
of treatment. This concurs with other studies in resource-
limited countries [11-13,15]. Failure to access this modal-
ity of treatment in our patients can be explained by the
fact that radiotherapy is not available in our center, and
therefore, patients requiring this form of treatment
had to travel long distances to receive radiotherapy at
the oncological center. This sad observation calls for
urgent establishment of radiotherapy services in our
center.
In this study, the postoperative complication rate was
22.0%, which is a higher rate than that reported by other
Chalya et al. World Journal of Surgical Oncology  (2015) 13:71 Page 8 of 9authors [13,15]. Surgical wound infection was the most
common complication but was usually superficial and eas-
ily controlled by local wound care. Additional operations
were required in nine (6.7%) patients who developed
postoperative complications, such as wound dehiscence,
Fournier’s gangrene, and urethral stricture (Table 3). These
required additional operations were associated with pro-
longed hospital stay and higher cost of treatment. The
median duration of hospital stay in our study was 14
days, which is higher than that reported in other studies
[11,13,15]. This can be explained by the high rate of post-
operative complications which required additional oper-
ation care and, subsequently, prolonged hospital stay.
Our overall mortality rate in the present study was
4.2% that is relatively lower than that reported in other
studies [15,35]. In the present study, mortality rate was
significantly high in HIV patients and in patients with
high stage and grade of the tumor and those who had
metastases and local recurrences.
In the present study, local recurrence was recorded in
5.3% of cases which is a higher rate than that reported by
other authors [35,36]. Tumor size, histological grade of
the tumor, stage of the tumor, and presence of metastasis
at the time of diagnosis were the main predictors of local
recurrence.
The follow-up of patients in this study was generally
poor, and data on long-term survival were not available.
This observation concurs with other reports done in de-
veloping countries [15,35]. Poor follow-up of patients in
our study may be explained by the fact that the majority
of patients were lost to follow-up at the end of the study
period. The potential limitation of this study is the fact
that the information about some patients was incom-
plete in view of the retrospective nature of the study,
and this might have introduced some bias in our findings.
Also, this study included only patients who were evaluated
and treated at a single institution, which may not reflect
the whole population in this region, despite the fact that
approximately 70% of oncologic patients in northwestern
Tanzania are managed at our center. However, despite this
limitation, the study has provided local data that can help
healthcare providers in the management of patients with
penile cancer. The challenges identified in the manage-
ment of penile cancer in our setting need to be addressed
in order to deliver optimal care for these patients.
Conclusions
Penile cancer is not rare in our environment affecting
mostly young adult males in their fourth decades of life,
uncircumcised with history of smoking and sexually trans-
mitted diseases including HIV. The majority of patients
present late with an advanced stage of the disease and a
high rate of inguinal lymph node metastasis. Late pres-
entation, poor accessibility to healthcare facilities, lackof advanced diagnostic and therapeutic facilities, lack of
radiotherapy services at our center, and lost to follow-up
are among the hallmarks of the disease in this region and
pose a great challenge in the management of these pa-
tients. Early recognition and aggressive treatment of penile
cancer and close follow-up are urgently needed to improve
outcomes in our environment. Health education is highly
needed to discourage patients with penile cancer from
presenting late to hospital when the disease is in its ad-
vanced stage. A high index of suspicion is required in the
management of chronic non-healing penile ulcers that
are recalcitrant to therapy and all suspected lesions should
be biopsied. In addition, encouraging neonatal circumci-
sion will go a long way towards reducing the incidence of
penile cancer in later life. Establishment of radiotherapy
services at our center is highly recommended.
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